Synbiotic acquires GECA Pharma

The cannabinoid start-up is thus adding the next company to its group of companies. With this, Synbiotic is now also entering the market for medical cannabis.

The cannabinoid company Synbiotic is taking over 100 percent of Cologne-based GECA Pharma GmbH. The Cologne-based company is to take over the pharmaceutical arm of the listed start-up in the future. "As one of the first German listed cannabis companies, we are thus tapping into the market for medicinal cannabis," says Synbiotic CEO Lars Müller.

Müller expects the market for medical cannabis to be worth several billion euros in the EU alone. Back in February, Synbiotic CEO Lars Müller spoke to Startbase about his big plans. The cannabinoid start-up is to become the leading provider in Europe. To achieve this, Synbiotic wants to take over more and more companies in order to expand its position. In March, Synbiotic acquired a stake in the Stuttgart-based start-up The Hempany. In April, it secured shares in the Canadian cannabinoid company NeuroTheryX.

According to Synbiotic, GECA Pharma is already profitable and generates almost 900,000 euros in sales from the trade of medicinal cannabis flowers alone.